We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Human Neurons Derived From Induced Pluripotent Stem Cells as a New Platform for Preclinical Drug Screening and Development

Fan Liao, PhD1; David M. Holtzman, MD1
[+] Author Affiliations
1Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St Louis, Missouri
JAMA Neurol. 2014;71(12):1475-1476. doi:10.1001/jamaneurol.2014.2802.
Text Size: A A A
Published online


Alzheimer disease (AD) is the most common dementia, with an estimated prevalence of 30 million people worldwide. Currently, there is no effective treatment that delays the onset or slows the progression of AD. β-Amyloid (Aβ), the key component of plaques, is thought to play a pivotal role in the initiation of AD pathogenesis.1 Previously, all clinical trials of Aβ-targeted therapeutics have failed. There are several possible reasons for this, one of which is that the preclinical drug discovery and development have relied mostly on cell lines or transgenic animals that overexpress Aβ. Testing drugs in human neurons was difficult because brain tissue is inaccessible through biopsies. After the finding that somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs), which can be further modified into specific types of cells,2,3 neurons induced from patients with familial and sporadic AD have been regenerated, characterized,4 and used to study aspects relevant to AD biology such as toxicity of Aβ oligomers.5

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles

Care at the Close of Life: Evidence and Experience
Alzheimer Disease: "It's OK, Mama, If You Want to Go, It's OK"

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Supplemental Content